Ann Hynes

I know you've said in the past that bolt-on M&A is your priority. Is that still the case

you have another $1.2 billion due in 2027, and another $2.3 billion in 2028

can you tell us what -- you had that initial 2026 outlook, what you're assuming the trend is in each segment

you talked about you see an increase in morbidity really driven by coding. Can you just talk about what states you're seeing that

do you have increased visibility on how those negotiations are going for the second half

Your $300 million cost program, can you remind us what you'll be annualizing as we exit 2026

if the biotech IPO really heats up market in Q4, how long does that usually end up?

what do you think, over time, this FDA change would -- how would that impact that kind of long-term growth algorithm for your company?

can you tell us what happened during that period versus what pricing is doing now?

Can you just elaborate how much growth? And what gives you confidence in that growth?

Can you just tell us where you ended in the health insurance business, where you ended from a margin perspective in each subsegment

what makes you a little bit more concerned - is it just less support from the CDC, and can you remind us how much of your--how many flu vaccines

what is the headwind to growth the first year of the implementation, and when would you expect that to turn positive

was there anything that came in better or worse than your expectations?

How do you view, you know, that many people going uninsured? How should we view that impact on Quest over the coming years?

I know you said Medicaid margins were tracking better than your expectations and what's embedded in guidance

should we assume that membership in your Medicaid book will actually decline next year and that coupled with rates. I'm just trying to figure out, like, will you have revenue actually declining

Several times, you talked about increased coding, I think Mark, in one of your responses, you noted that HICS, you saw increased coding. Can you just elaborate on those comments

Can you actually remind us what is embedded in guidance, meaning are you assuming 2024 trends growing high single digits or mid-single digits

Do you have any color on maybe from a timing perspective when that could be approved

Can you just go into more of the resiliency programs, provide some more detail on what's up that $400 million and obviously, the confidence and executing throughout the year

Can you remind us what states are still pending? And any quantification of what could be incremental would be great

Can you just provide more details on your resiliency programs? I think the Street really at this point, doesn't believe that the subsidies will be extended

I know you reiterated guidance, but are there any major changes in assumptions embedded in that reiteration of guidance?

How much impact do you think that had on inpatient admissions in 2024? And do you think it will continue to be a benefit?

it looks like IBNR grew about 35% sequentially, and this is versus a 22% membership growth when looking at just total Medicare Advantage

How did your expectations for 2026 change versus your thoughts on Investor Day?

can you give an update on your diversification strategy? I know you're trying to shift some members out of H5216

Can you talk about what cost trend is actually better than your expectations? And within that, can you just talk about Medicaid is doing

What is the V28 headwind in 2026 MA rates versus the 160 basis bps in 2025?

I just want to focus on 2025 MLR guidance. Can you just break down the levers of the increase? What base are you assuming?

What do you think they need the most clarity on to accelerate projects? Is it [ MFN ] pricing? Is it clarity on maybe tariffs

where do you think maybe you're being the most conservative? And alternatively, where do you think the biggest risks are?

do you think there's any change to the competitive landscape in the diagnostic business?

Maybe how we should think about PAMA going into 2026. Do you think the risk has increased of those cuts coming back?

Can you let us know how much tariffs now are embedded in guidance? And I'm assuming that implies the underlying operations are doing better

With Medicaid disenrollment and the expiration of the ACA subsidies, how is that trending versus your expectation? And does your guidance assume deterioration of collectability on copays and deduct...

can you let us know what you're assuming surgical volume versus medical volume? And then with the Nevada market, how does that market do in 2025?

what was the driver of that? And I think you said in guidance, you assume it's gonna accelerate to 2.5% to 3%. Can you just tell us what the drivers of that acceleration is?

Can you remind us what they actually were in 2024 and what you expect in 2025?

Can you share some maybe targets you have on how you think AI will -- from the cost side, maybe like SG&A

Is up 10%. You tell us what that is Medicare, Medicaid and commercial?

At the last call, I believe, you said margins should be in the negative 1% to negative 1.5% range. Is that still a good bogey

can you remind us what your target margin is for Medicaid and what you would expect it to be in 2026